Revance Therapeutics, Inc. (NASDAQ:RVNC) recovered 7.49% of its value since hitting low of $16.56. The recent move of 4.03% gain helped the stock to close at $17.8 when trading ended on 02/11/2019. At recent session, the prices were hovering between $16.81 and $17.82. This company shares are 173.88% off its target price of $48.75 and the current market capitalization stands at $756.5M. The recent change has given its price a -7.79% deficit over SMA 50 and -48.48% deficit over its 52-week high. The stock witnessed -9.78% declines, -26.26% declines and -32.7% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found RVNC’s volatility during a week at 3.99% and during a month it has been found around 4.62%.Revance Therapeutics, Inc. (RVNC) Top Holders
Institutional investors currently hold around $586 million or 82.8% in RVNC stock. Look at its top three institutional owners. Wellington Management Group Llp owns $68.7 million in Revance Therapeutics, Inc., which represents roughly 9.08% of the company’s market cap and approximately 11.72% of the institutional ownership. Similar statistics are true for the second largest owner, Jpmorgan Chase & Co, which owns 3,646,611 shares of the stock are valued at $62.39 million. The third largest holder is Essex Woodlands Management, Inc., which currently holds $57.18 million worth of this stock and that ownership represents nearly 7.56% of its market capitalization.Revance Therapeutics, Inc. 13F Filings
At the end of September reporting period, 50 institutional holders increased their position in Revance Therapeutics, Inc. (NASDAQ:RVNC) by some 2,783,643 shares, 41 decreased positions by 1,863,189 and 29 held positions by 29,618,270. That puts total institutional holdings at 34,265,102 shares, according to SEC filings. The stock grabbed 16 new institutional investments totaling 567,399 shares while 11 institutional investors sold out their entire positions totaling 534,581 shares.Revance Therapeutics, Inc. (NASDAQ:RVNC) Insider Trades
Multiple company employees have indulged in significant insider trading. Revance Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Principal Accounting Officer Allouche Cyril has sold 625 shares of Revance Therapeutics, Inc. (RVNC) in trading session dated Jan. 22, 2019. These shares are worth $11,106 and were traded at $17.77 each. The SEC filing shows that Allouche Cyril performed a sale of 375 shares. The Principal Accounting Officer disposed these shares by way of transaction on Jan. 03, 2019. The company’s shares were given away at $19.48 per share worth to an income of some $7,305 on account of Allouche Cyril.
Principal Accounting Officer, Allouche Cyril, sold 491 common shares of Revance Therapeutics, Inc. (RVNC) in the open market. In a transaction dated Nov. 20, 2018, the shares were put up for sale at an average price of $20.66, raking in a sum of $10,144. After this sale, 4,000 common shares of RVNC are directly owned by the insider, with total stake valued at $71,200.
In the transaction dated Nov. 09, 2018, the great number of shares disposed came courtesy the Principal Accounting Officer; Allouche Cyril disposed a total of 2,188 shares at an average price of $23.72, amounting to approximately $51,899. The insider now directly owns 4,750 shares worth $84,550.Revance Therapeutics, Inc. (RVNC) Analyst Guide
Several analysts have released their opinion on Revance Therapeutics, Inc. (NASDAQ:RVNC), with 3 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 6 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.8 average brokerage recommendation.